Article

Effects of everolimus monotherapy on hematological parameters and iron homeostasis in de novo liver transplant recipients: preliminary results.

Liver and Multivisceral Transplant Center, University of Modena, Modena, Italy.
Transplantation Proceedings (Impact Factor: 0.95). 07/2008; 40(6):1947-9. DOI: 10.1016/j.transproceed.2008.05.068
Source: PubMed

ABSTRACT Anemia after orthotopic liver transplantation (OLT) is a common complication due to several reasons. Immunosuppressive drugs play an important role in anemia occurring at 1 month or more after OLT. Several studies describe myelosuppression immunosuppressants such as the mammalian target of rapamycin inhibitors.
We performed a single-center, prospective trial consisting of a short 30-day course of cyclosporine (CsA) associated with everolimus (EVL) from postoperative day 10 (Group EVL) versus a CsA immunosuppressive regimen (Group CsA) in de novo OLT patients. We explored the influence of immunosuppressive drugs on hematological parameters comparing EVL versus CsA.
Twenty-eight patients were enrolled in the EVL and 12 in the CsA Groups. After OLT, hemoglobin (Hb), hematocrit (Hct), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), white blood cell (WBC), platelets (PLT), transferrin saturation (TSAT), iron, ferritin, and transferrin did not differ significantly between the 2 groups at any time point. Among the patients who reached 6-months of follow-up, 5 (41.7%) EVL and 4 (80%) CsA subjects were anemic (P=not significant [NS]). Only anemia in patients enrolled in Group EVL showed a trend toward the features of microcytic, hypochromic anemia.
Our results demonstrated that de novo anemia in OLT patients treated with EVL monotherapy showed the same incidence as in patients treated with CsA. Hb values remained similar during the entire follow-up. Moreover, overall myelosuppression in the EVL Group was not significantly different from patients in the CsA Group.

0 Bookmarks
 · 
39 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Everolimus, which inhibits the mammalian target of rapamycin, is increasingly used in breast cancer and familiarity with its full range of toxicity is critical for practicing oncologists. Methods We studied hematologic changes in 31 patients with metastatic breast cancer treated in a phase-II clinical trial using everolimus. Complete Blood Counts were collected at baseline, 2 weeks, 4 weeks, every 4 weeks on treatment, and one month after discontinuation. Adverse events were defined using Common Toxicity Criteria version 3. Linear mixed models with fixed effects of time and random intercepts and slopes were used to study trends and comparisons were conducted using paired t-tests. Results Anemia was reported in 22 patients (71%), thrombocytopenia in 17 (55%), and leukopenia in 14 (45%). These were predominantly grade ½ and did not require dose modification. Red blood cell mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH) both decreased significantly over time (P<0.0001) starting at 2 weeks with no significant change in mean corpuscular hemoglobin concentration (MCHC) (P=0.104). Both MCV and MCH increased one month after treatment discontinuation (P values <0.0001 and 0.0003, respectively) indicating reversibility of this effect. While total leukocyte counts remained largely stable, lymphocyte percentage progressively decreased over time with a trend for increased neutrophils. Conclusions In addition to anemia, leukopenia, and thrombocytopenia, everolimus consistently induces red cell microcytosis and reduced hemoglobin content. Lymphopenia may contribute to immunesuppression and increased risk of infection. Familiarity with these hematologic changes is prudent as more patients are treated with this class of drugs.
    Clinical Breast Cancer 08/2014; 15(1). · 2.63 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We studied whether the use of sirolimus with reduced-dose tacrolimus, as compared to standard-dose tacrolimus, after liver transplantation is safe, tolerated and efficacious. In an international multicenter, open-label, active-controlled randomized trial (2000-2003), adult primary liver transplant recipients (n = 222) were randomly assigned immediately after transplantation to conventional-dose tacrolimus (trough: 7-15 ng/mL) or sirolimus (loading dose: 15 mg, initial dose: 5 mg titrated to a trough of 4-11 ng/mL) and reduced-dose tacrolimus (trough: 3-7 ng/mL). The study was terminated after 21 months due to imbalance in adverse events. The 24-month cumulative incidence of graft loss (26.4% vs. 12.5%, p = 0.009) and patient death (20% vs. 8%, p = 0.010) was higher in subjects receiving sirolimus. A numerically higher rate of hepatic artery thrombosis/portal vein thrombosis was observed in the sirolimus arm (8% vs. 3%, p = 0.065). The incidence of sepsis was higher in the sirolimus arm (20.4% vs. 7.2%, p = 0.006). Rates of acute cellular rejection were similar between the two groups. Early use of sirolimus using a loading dose followed by maintenance doses and reduced-dose tacrolimus in de novo liver transplant recipients is associated with higher rates of graft loss, death and sepsis when compared to the use of conventional-dose tacrolimus alone.
    American Journal of Transplantation 01/2014; · 6.19 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To assess our experience with the use and management of everolimus-based regimens post-liver transplantation and to redefine the potential role of this drug in current clinical practice.
    World journal of transplantation. 06/2014; 4(2):122-32.